Showing results (51-60 of 132) with videos related to
Sort By:
Pageof 14
Clinical Pharmacokinetics|September 15, 2007
Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradoxS William Tam, Michael L Sabolinski, Manuel Worcel, et al.Circulation. Heart Failure|March 14, 2014
Prognostic value of soluble ST2 in the Valsartan Heart Failure TrialInder S Anand, Thomas S Rector, Michael Kuskowski, et al.Circulation. Heart Failure|June 28, 2014
Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: results from the African-American Heart Failure TrialInder S Anand, Sithu Win, Thomas S Rector, et al.Journal of the American College of Cardiology|October 24, 2002
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitorsAldo P Maggioni, Inder Anand, Sidney O Gottlieb, et al.Circulation|August 27, 2003
Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure TrialJay N Cohn, Inder S Anand, Roberto Latini, et al.European Journal of Heart Failure|January 8, 2013
Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFTInder S Anand, Thomas S Rector, Michael Kuskowski, et al.Congestive Heart Failure (Greenwich, Conn.)|October 5, 2010
Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT)Javed Butler, Inder S Anand, Michael A Kuskowski, et al.American Heart Journal|July 3, 2002
The cardiac component of cardiac cachexiaViorel G Florea, Michael Y Henein, Mathias Rauchhaus, et al.Circulation|October 7, 2009
Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failureInder S Anand, Kalkidan Bishu, Thomas S Rector, et al.Circulation. Heart Failure|October 8, 2009
Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure TrialInder S Anand, Thomas S Rector, Michael Kuskowski, et al.Pageof 14